The market for treatments targeting macular degeneration, recognized as the leading cause of blindness in the elderly, is ...

If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

This retrospective study included patients with a defined ophthalmological status who received intravitreal brolucizumab injections to treat neovascular AMD at the Seoul Asan Medical Center between ...

Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes. Persistent ...

The aim of the present study was to investigate changes in metamorphopsia in patients with diabetic macular edema (DME) following intravitreal aflibercept injection (IVA) with the treat and extend ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the first of a three-part series on dry ...

Please provide your email address to receive an email when new articles are posted on . Steven Yeh, MD, of Truhlsen Eye Institute, University of Nebraska Medical Center, said by 4 weeks, patients with ...

Many surgeons admit that medical robots can now operate with greater precision than human specialists. However, the complex preparation required for robotic surgery still takes far too long. But a new ...